Synnovation Therapeutics Inc. has discovered new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligases binding moiety coupled to nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2)-targeting moiety potentially useful for the treatment of cancer.